Controversy of tissue-agnostic approvals in immunotherapy and targeted therapy

In recent years, approval of some immunotherapy based on markers such as dMMR, tumour mutational burden and other few such markers is not received well as shown in post-approval data published. The context of such approvals and controversies is discussed briefly.

Saved in:
Bibliographic Details
Published inMedical oncology (Northwood, London, England) Vol. 39; no. 6; p. 67
Main Author Bose, Chinmoy K.
Format Journal Article
LanguageEnglish
Published New York Springer US 01.05.2022
Springer Nature B.V
Subjects
Biomarkers, Tumor
Cancer therapies
Colorectal cancer
Conflicts of interest
Decision making
Drugs
FDA approval
Hematology
Humans
Immunologic Factors
Immunotherapy
Internal Medicine
Lung cancer
Medicine
Medicine & Public Health
Melanoma
Metastasis
Monoclonal antibodies
Mutation
Neoplasms - drug therapy
Oncology
Pathology
Pediatrics
Prostate cancer
Response rates
Sarcoma
Short Communication
Targeted cancer therapy
Thyroid gland
Tumors
)
Immune checkpoint inhibitor (ICI)
Pembrolizumab
Microsatellite instability (MSI)
Deficient mismatch repair (d
Tumour mutational burden (TMB)
NTRK
Deficient mismatch repair (dMMR)
Online AccessGet full text

Cover

More Information
Summary:In recent years, approval of some immunotherapy based on markers such as dMMR, tumour mutational burden and other few such markers is not received well as shown in post-approval data published. The context of such approvals and controversies is discussed briefly.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1559-131X
1357-0560
1559-131X
DOI:10.1007/s12032-022-01672-5